FDA grants fast track, RMAT designations to CAR-T for advanced non-Hodgkin lymphoma

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
The fast track designation applies to patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The regenerative medicine advanced therapy (RMAT) designation applies to patients with relapsed or refractory large B-cell lymphoma.
CB-010 (Caribou Biosciences) is an allogeneic, CD19-directed CAR T-cell therapy.
The investigational agent is genetically engineered using CRISPR/Cas9

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
The fast track designation applies to patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The regenerative medicine advanced therapy (RMAT) designation applies to patients with relapsed or refractory large B-cell lymphoma.
CB-010 (Caribou Biosciences) is an allogeneic, CD19-directed CAR T-cell therapy.
The investigational agent is genetically engineered using CRISPR/Cas9